Browsing by Author "Bal, Ajda"

Now showing 1 - 3 of 3

Characteristics of patients with rheumatoid arthritis in Turkey: Results from the Turkish league against rheumatism rheumatoid arthritis registry
(Turkish League Against Rheumatism, 2015-01-01) Bal, Ajda; Ataman, Şebnem; Bodur, Hatice; Rezvani, Aylin; Paker, Nurdan; Taştekin, Nurettin; Karatepe, Altınay Göksel; Borman, Pınar; Yener, Mahmut; Nas, Kemal; Sezgin, Melek; Yazgan, Pelin; Tekeoğlu, İbrahim; Doğu, Beril; Altay, Zühal; Kırnap, Mehmet; Gürğan, Alev; Gür, Ali; Hizmetli, Sami; Günendi, Zafer; Erdem, Rana; Uğurlu, Hatice; İnal, Elem; Ölmez, Neşe; Kozanoğlu, Erkan; Öken, Öznur; Özel, Sumru; Dündar, Ümit; Akıncı, Ayşen; Öztürk, Cihat; Sivrioğlu, Koncuy; Duruöz, Mehmet Tuncay; Aydoğ, Ece; Çapkın, Erhan; Altan, Lale; Evcik, Deniz; Durmuş, Oğuz; Yağcı, İlker; Şendur, Ömer Faruk; Sertpoyraz, Filiz Meryem; Özgül, Ahmet; Şenel, Kazım; Çapacı, Kazım; SİVRİOĞLU, KONÇUY; ALTAN İNCEOĞLU, LALE; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; 0000-0002-4296-9480; AAG-8211-2021; AAH-1652-2021
Objectives: This study investigates the demographic and clinical characteristics of patients with rheumatoid arthritis (RA) in Turkey, and attempts to identify strategies for the prevention, treatment, and support of RA.Patients and methods: A total of 2,359 patients (1,966 females, 393 males; mean age 51.6 +/- 12.5 years; range 18 to 75 years) with RA from 36 centers across Turkey, who were recorded in the Turkish League Against Rheumatism (TLAR) RA Registry between September 2007 and March 2011, were evaluated. Patients' demographic and clinical data were recorded. Disease activity, functional status, and radiographic damage were measured using the Disease Activity Score 28, the Health Assessment Questionnaire, and van der Heijde modified Sharp scoring method.Results: The mean duration of academic education received was 5.2 +/- 3.8 years, and 74.6% of the patients were homemakers. Non-biological disease-modifying anti-rheumatic drugs were used by 91.0% of the patients, while 10.2% used biological disease-modifying anti-rheumatic drugs. The mean Disease Activity Score 28, Health Assessment Questionnaire, and Sharp scores were 4.0 +/- 1.4, 0.38 +/- 0.37, and 31.2 +/- 57.1, respectively. Of the patients, 17.8% were in remission and 14.1% had low disease activity rates, while 42.7% and 25.5% had moderate and high disease activity rates.Conclusion: The majority of patients with RA in Turkey are middle-aged homemakers. Despite the high rates of disease-modifying anti-rheumatic drugs use, the majority of patients had moderate and high disease activity. These findings indicate that treatment needs of RA patients are not met sufficiently.
Quality of life and related variables in patients with ankylosing spondylitis
(Springer, 2011-05) Bodur, Hatice; Ataman, Şebnem; Rezvani, Aylin; Buğdaycı, Derya Soy; Çevik, Remzi; Birtane, Murat; Akıncı, Ayşen; Altay, Zuhal; Günaydın, Rezzan; Yener, Mahmut; Koçyiğit, Hikmet; Duruöz, Tuncay; Yazgan, Pelin; Çakar, Engin; Aydın, Gülümser; Hepgüler, Simin; Kırnap, Mehmet; Ölmez, Neşe; Soydemir, Raikan; Kozanoğlu, Erkan; Bal, Ajda; Karkucak, Murat; Günendi, Zafer; Altan, Lale; Sivrioğlu, Koncuy; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; 56245687600; 6603281363
To evaluate quality of life (QoL) and related variables in patients with ankylosing spondylitis (AS), a chronic inflammatory disease of the spine. Nine-hundred and sixty-two patients with AS from the Turkish League Against Rheumatism AS Registry, who fulfilled the modified New York criteria, were enrolled. The patients were evaluated using the Assessment of SpondyloArthritis International Society core outcome domains including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), fatigue (BASDAI-question 1), pain (last week/spine/due to AS), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Radiology Index (BASRI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and two QoL questionnaires (the disease-specific ASQoL and generic the Short Form-36 [SF-36]). The mean ASQoL score was 7.1 +/- A 5.7. SF-36 subscales of general health, physical role and bodily pain had the poorest scores. ASQoL was strongly correlated with disease duration, BASDAI, fatigue, BASFI, BASMI, BASRI, MASES, pain and SF-36 subscales (P < 0.001). SF-36 subscales were also strongly correlated with BASDAI and BASFI. Advanced educational status and regular exercise habits positively affected QoL, while smoking negatively affected QoL. In patients with AS, the most significant variables associated with QoL were BASDAI, BASFI, fatigue and pain. ASQoL was noted to be a short, rapid and simple patient-reported outcome (PRO) instrument and strongly correlated with SF-36 subscales.
Turkish compliance and adaptation of EULAR 2013 recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: Expert opinion of TLAR
(Turkish League Against Rheumatism, 2015-05-27) Ataman, Şebnem; Sürmeli, Zühre Sarı; Sunar, İsmihan; Özdemirel, Erhan; Akıncı, Ayşen; Bodur, Hatice; Akgul, Ozgur; Altan, Lale; Altay, Zuhal; Ayhan, Figen; Birtane, Murat; Soy Buğdaycı, Derya; Capkin, Erhan; Cerrahoglu, Lale; Duruoz, Mehmet Tuncay; Gunaydin, Rezzan; Gunendi, Zafer; Gurer, Gulcan; Bal, Ajda; Kacar, Cahit; Kaptanoglu, Ece; Kaya, Taciser; Kocabas, Hilal; Kotevoglu, Nurdan; Nas, Kemal; Rezvani, Aylin; Sen, Nesrin; Sendur, Omer Faruk; Yalcin, Peyman; ALTAN İNCEOĞLU, LALE; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; AAH-1652-2021
Objectives: This study aims to report Turkish League Against Rheumatism's assessment on the compliance of European League Against Rheumatism 2013 treatment recommendations for rheumatoid arthritis with practices in Turkish rheumatology clinics and adaptations for Turkey.Materials and methods: Members of Turkish League Against Rheumatism and one rheumatoid arthritis patient voted for the 2013 recommendations of the European League Against Rheumatism for treatment of rheumatoid arthritis in two sessions. An item was changed and voted again only if at least 70% of participants wanted a change. Strength of recommendations was calculated for the items. Strength of recommendations for the changed items in the first and second voting rounds was compared by Wilcoxon signed-rank test. In case of significant difference, the item with higher strength of recommendation was accepted. In case of no difference, the changed item was selected.Results: Three overarching principles and fourteen recommendations were assessed among which the three overarching principles were changed emphasizing the importance of physiatrists as well as rheumatologists for taking care of the patients. Third item was changed by adding composite indices for assessing disease activity. In the ninth recommendation, rituximab was suggested as a first line drug independent of situations like latent tuberculosis or lymphoma, etc. In the 11th recommendation, unlike European League Against Rheumatism, our committee did not suggest any thought about tofacitinib, as then it had not been approved in Turkey. Remaining principles were accepted as the same.Conclusion: Expert opinion of Turkish League Against Rheumatism for treatment of rheumatoid arthritis patients was formed for practices in Turkish clinics.